IDEAS home Printed from https://ideas.repec.org/a/spr/drugsa/v45y2022i12d10.1007_s40264-022-01248-2.html
   My bibliography  Save this article

Characterization of Serous Retinopathy Associated with Cobimetinib: Integrated Safety Analysis of Four Studies

Author

Listed:
  • Giulio Barteselli

    (Genentech, Inc. (a Member of the Roche Group))

  • Grant R. Goodman

    (Genentech, Inc. (a Member of the Roche Group))

  • Yogesh Patel

    (F. Hoffmann-La Roche Ltd)

  • Ivor Caro

    (Genentech, Inc. (a Member of the Roche Group))

  • Cloris Xue

    (Hoffmann-La Roche Ltd)

  • Samuel McCallum

    (Genentech, Inc. (a Member of the Roche Group))

Abstract

Introduction and Objective Serous retinopathy can be associated with MEK inhibitors, including cobimetinib. We present results of an integrated safety analysis to further characterize ocular functional and structural changes due to serous retinopathy. Methods Four studies evaluating cobimetinib at the approved dose and schedule in combination with other oncology drugs were included. Study CO39721 incorporated standardized ophthalmologic assessments to fully characterize serous retinopathy events over time and was the primary study for analysis. Supporting information was provided by studies GO28141, WO29479, and GO30182. Results In total, 655 patients received one or more doses of cobimetinib and comprised the safety-evaluable population. Overall, 117 patients (17.9%) had one or more serous retinopathy events, 24 (3.7%) had two or more events, and four (0.6%) had three or more events. Grade 3 events occurred in

Suggested Citation

  • Giulio Barteselli & Grant R. Goodman & Yogesh Patel & Ivor Caro & Cloris Xue & Samuel McCallum, 2022. "Characterization of Serous Retinopathy Associated with Cobimetinib: Integrated Safety Analysis of Four Studies," Drug Safety, Springer, vol. 45(12), pages 1491-1499, December.
    • Handle: RePEc:spr:drugsa:v:45:y:2022:i:12:d:10.1007_s40264-022-01248-2
    DOI: 10.1007/s40264-022-01248-2
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40264-022-01248-2
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40264-022-01248-2?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:45:y:2022:i:12:d:10.1007_s40264-022-01248-2. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.